Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in IsraelTrialog Clinical Trials Ltd to supply trial drugs and provide…
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene.
Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in Acute Myeloid Leukemia (AML) patients with extramedullary diseaseThe study led by Associate Professor Anoop Enjeti…
20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Michael Kelso as Principal Scientist. Prof Kelso will be responsible for providing scientific leadership,…
Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond. https://www.youtube.com/watch?v=Yf66wmZtcCc
